International AIDS Society 2025

International AIDS Society 2025
July 13-17, 2025
Kigali, Rwanda

International AIDS Society 2025.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (15)

    Lenacapavir Dosing in Special Situations: Tuberculosis and Beyond

    • Author(s): Bekker, L-G
    • yeztugo
    • HIV / AIDS
    • Oral

    Estimation of the Counterfactual HIV Incidence in the PURPOSE Trials

    • Author(s): Kelley, C
    • yeztugo
    • descovy
    • truvada
    • HIV / AIDS
    • Oral

    Vesatolimod Pharmacodynamic Responses in a Trial of Vesatolimod and bNAbs in Early-Treated South African Women with Clade C HIV-1

    • Author(s): Cai, Y
    • vestalimod (gs-9620)
    • HIV / AIDS
    • Poster

    HIV-Specific T-Cell Responses in Suppressed People with HIV-1 Receiving Lenacapavir, Teropavimab, and Zinlirvimab

    • Author(s): Cai, Y
    • sunlenca
    • bnab combination (gs-5423, gs-2872)
    • HIV / AIDS
    • Oral

    Satisfaction, Preference, and Health-Related Quality of Life Changes Using HIV-Specific Patient-Reported Outcome Measures with a Novel, Twice-Yearly Administered HIV-1 Treatment Regimen

    • Author(s): Gaur, A
    • sunlenca
    • HIV / AIDS
    • Poster

    Exploratory Qualitative Analysis of the Acceptability of HIV Prevention Methods Among Pregnant and Lactating Women Interviewed During the Randomized Blinded Phase of PURPOSE 1

    • Author(s): Nyamaizi, A
    • yeztugo
    • HIV / AIDS
    • Poster

    Long-Term Persistence, Effectiveness, Safety, and Metabolic Impact of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination in Treatment-Naïve and Experienced People Living with HIV in a Large Latin American Cohort

    • Author(s): Cecchini, DM
    • biktarvy
    • HIV / AIDS
    • Poster

    Real-World Liver Outcomes in People with HIV and Hepatitis

    • Author(s): Chuo, CY
    • viread
    • HIV / AIDS
    • Poster

    Inclusion of Pregnant and Lactating People in the PURPOSE 1 Study: Efficacy, Safety, and PK

    • Author(s): Bekker, L-G
    • yeztugo
    • descovy
    • truvada
    • HIV / AIDS
    • Oral

    Efficacy, Safety, and PK of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among Adolescents and Young People in the Phase 3 Trials PURPOSE 1 and PURPOSE 2

    • Author(s): Gill, K
    • yeztugo
    • HIV / AIDS
    • Oral

    Synergizing Expertise: Lessons Learned from Conducting the first HIV Cure Interventional Trial in Africa with Collaboration Between Academia, Government, and Industry

    • Author(s): Dong, K
    • vestalimod (gs-9620)
    • HIV / AIDS
    • Poster

    Preference for Twice-Yearly Injections vs Daily Oral Pills for HIV PrEP in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People Enrolled in PURPOSE 2

    • Author(s): Mngadi, K
    • yeztugo
    • truvada
    • HIV / AIDS
    • Oral

    Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes

    • Author(s): Mujuru, HA
    • descovy
    • HIV / AIDS
    • Poster

    Predictors of HIV PrEP Preferences Using the Health Belief Model: Twice-Yearly Subcutaneous Lenacapavir vs Daily Pills in the PURPOSE 1 Trial

    • Author(s): Mansoor, L
    • yeztugo
    • HIV / AIDS
    • Poster

    Factors Impacting Women's Choice of PrEP Product After the Randomized Blinded Phase of PURPOSE 1

    • Author(s): Palanee-Phillips, T
    • yeztugo
    • HIV / AIDS
    • Poster